P61 DNA-vaccines against melanoma: Design and investigation of antigenic properties by Starostina, E. et al.
were observed. In patient with stomach adenomas, degree of
atrophy increases as the pepsinogen I/pepsinogen II ratio
decreases, the ability of immune cells to produce IL-18 under
the influence of PA stimulates proliferation of cells, including
atypical.
Conclusion: Findings suggest the ability of blood cells to pro-
duce TNFa, IL-18 and IFNc under the influence of polyclonal acti-
vators was higher in patients with stomach adenomas than in
patients with stomach adenocarcinomas. In patients with adeno-
carcinomas the decline in the production of cytokines with both
the proliferative and antiproliferative effects indicates radical
changes in the cytokine-producing capability of immunocompe-
tent cells when malignant neoplasm became mature.
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Background: Tumour-associated macrophages (TAM) derived
from peripheral blood monocytes are a key immune regulatory
component of tumour microenvironment (Qian, Pollard, 2010).
Advanced clinically applicable strategy for TAM targeting is their
functional reprogramming (Wynn et al., 2013). Monocytes/
macrophages are heterogeneous and versatile cells. Two major
macrophage subpopulations with different functions which rep-
resent extreme of a continuum in a universe of activation states,
including classically activated/inflammatory (M1) and alterna-
tively activated/regenerative (M2) macrophages, have long been
recognized (Zhou et al., 2014). CD68 and CD163 are the general
markers of M1 and M2 subsets respectively (Hoene et al., 2015,
Tedesco et al., 2014). However, there are different markers
expressed on surface of monocytes/macrophages that reflected
some special functional activities of these cells. Thus, expression
of CD119(IFN-cR) or CD124(IL-4R) reflects the predisposition to M1
or M2-polarisation by suitable cytokines IFN-c and IL-4 (Tedesco
et al., 2014). The pro-inflammatory marker CD282 (TLR2) is asso-
ciated with antibacterial function. Anti-inflammatory CD36+ cells
take part in scavenging of apoptotic remains and inducing IL-10
production. Although monocytes/macrophages could undergo
their phenotypically/functionally dynamic switch in response to
the microenvironment signals there is some predisposition of
their status in peripheral blood to polarization in tissues. Modula-
tion of monocyte peripheral status before their infiltration is an
attractive target for cancer therapeutic approaches.
The aim is to study phenotypic subsets of peripheral blood
monocytes in breast and gastric cancer patients.
Materials and methods: 8 breast cancer and 8 gastric cancer
patients T1N0-3M0 treated in Tomsk Cancer Institute were
enrolled in investigation. The diagnosis was histologically veri-
fied. Phenotypic features were assessed by flow cytometry using
mAb CD119(IFN-cRa), CD124(IL-4R), CD282 (TLR2), CD36, CD68,
CD163 (BD Pharmingen) before treatment and in 5 days after sur-
gery of tumour.
Results: We found that amounts of monocytes expressing
main surface markers of M-1 or M2-type activation in peripheral
blood in cancer patients wasn’t large: CD68+ and CD163+ cells
were 4.18 ± 3.41% and 7.64 ± 3.75% of whole pool of monocytes
respectively. This finding supports the fact that in general
M1/M2-polarization of monocytes/macrophages occurs in local
tissues by specific micro- environmental conditions [Ambarus
et al., 2012, Zhou et al., 2014]. But high levels of CD119(IFN-cR)+
monocytic cells (87.36 ± 12.08%) in peripheral blood showed that
predisposition to M1-polarization of circulating monocytes exists
in cancer patients, because it’s known IFN-c significantly
increased the fraction of surface CD68 – expressing cells and
down-regulated expression of the M2 markers in vitro [Tedesco
et al., 2014]. Expression of CD124 (IL-4R) was detected only in
26.81 ± 8.11% of monocytes in cancer patients. The subset of
pro-inflammatory CD282+ (TLR2) circulating monocytes
amounted 64.38 ± 9.47% of total count of monocytic cells. Anti-
inflammatory CD36+ monocytes were 35.66 ± 7.00%. It is notewor-
thy this subset was 48.43 ± 8.13% in breast cancer patients and
only 22.88 ± 9.86% in gastric cancer patients (p < 0.05).
On the 5-th day after surgery, we detected decrease in CD282+
cells from 80.90 ± 8.55% to 38.70 ± 9.47% of total monocytes count
in breast cancer patients (p < 0.05). Another noticeable feature of
monocytes pool after operation was increasing of anti-
inflammatory CD36+monocytes as in breast (1.69-fold) and
gastric (1.97 fold) cancer patients.
Conclusion: There were a small accounts of M1 (CD68+) or M2
(CD163+) polarized monocytes in peripheral blood in breast and
gastric cancer patients. INF-c(CD119)+ and CD282(TLR2)+ pro-
inflammatory subsets were dominated in cancer patients. The
high levels of CD36+monocytes was the feature of breast cancer
patients as compared with gastric cancer ones. Surgery removal
of tumour was associated with increasing of CD36+ monocytes
in both breast and gastric cancer and with decreasing of CD282
(TLR2)+ monocytes in breast cancer.
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Melanoma is the most aggressive and dangerous skin cancer.
In 2013 about 23.8% of patients developed III–IV stages of a
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disease in Russia (http://clinical-pharmacy.ru). The most com-
mon approaches to control melanoma are surgical resection,
chemotherapy, radiotherapy, and immunotherapy (Wildemore
et al., 2001). In the case of immunotherapy interferon prepara-
tions are the most commonly used, however, it is impossible to
increase overall survival rate. Vaccine therapy is more promising
method including engineered DNA-vaccines. The goal of this
work is to design and study candidate DNA-vaccines against
melanoma pMEL-TCI-A0201 and pMEL-TCI in vitro and ex vivo.
Using original software we designed two T-cell immunogens
MEL-TCI-A0201 and MEL-TCI which are candidate DNA-vaccines
against melanoma. The first allele-specific immunogen MEL-
TCI-A0201 comprises CTL-epitopes restricted by only one allelic
variant HLA-A*0201 that is prevailing in global population. The
second universal immunogen MEL-TCI comprises CTL-epitopes
restricted by 12 major allelic variants of HLA class I molecules.
Furthermore, DNA-construct pcDNA-mart1 carrying full-length
variant of antigen MART-1 was designed. This construct was used
as a positive control. Genes encoding target immunogens have
been synthesized and cloned into vector plasmid DNA3.1 (Ant-
onets et al., 2010, Bazhan et al., 2010). Evidence of the target genes
expression in vitro after transfection of 293T-cells with obtained
DNA-vaccine constructs p MEL-TCI and pMEL-TCI-A0201 were
evaluated using three methods: reverse transcription-PCR to
determine specific polyepitope immunogen mRNA; western
immunoblotting assay with 29F2 monoclonal antibodies to
‘‘marker” epitope at the C-terminus of the polyepitope constructs;
flow cytometry assay of stained 293T cells transfected with
obtained plasmids using FITC-labeled 29F2 monoclonal antibod-
ies. It was shown that all obtained plasmids were provided
expression of target genes in eukaryotic cells.
Plasmids pMEL-TCI and pMEL-TCI-A0201 were used for trans-
fection of human monocyte derived dendritic cells to estimate
capacity of polyepitope constructs to induce specific T-cell
immune response by IFNc ELISpot analysis ex vivo. The study
was carried out in collaboration with researchers from laboratory
of molecular immunology at Scientific Research Institute of Clin-
ical immunology, Siberian Branch, Russian Academy of Medical
Sciences. License for conducting the study was approved by the
local ethic committee at this institute. Cell culture of human mel-
anoma Mel Is (HLA-A*0201+, MART-1+) was kindly provided by N.
N. Blokhin Russian Cancer Research Center (RAMS) and was used
as target cells. Monocyte suspension and suspension of
co-incubated monocytes with dendritic cells transfected with
vector plasmid DNA3.1 were used as negative controls.
Co-incubated monocytes with dendritic cells transfected with
plasmid pcDNA-mart1, encoding full-length melanoma antigen
MART-1, were used as positive control. It was shown that in the
presence of melanoma cell lysates co-incubated with monocytes
and dendritic cells transfected with plasmids pMEL-TCI-A0201
and pcDNA-mart1 (positive control) reliably more IFNc-
producing cells are detected compared with negative control
samples in the presence of lysate of melanoma cells.
Thus, it was shown that obtained plasmids pMEL-TCI-A0201,
pMEL-TCI, and pcDNA-mart1 are able to provide expression of
target proteins in eukaryotic cells. Moreover using IFNc ELISpot
assay we demonstrated that DNA vaccine pMEL-TCI-A0201
induced T-cell immune response against human melanoma anti-
gens and its efficiency is equal to full-length melanoma antigen
MART-1.
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Over time, study of malignant tumours was concentrated on
cancer cells only. Now, however, an important role of cancer cell
microenvironment and interactions cell with extracellular matrix
(ECM) is becoming evident. Tumour cells modify normal ECM to
cancer-associated matrix (CAM) thereby creating favorable condi-
tions for the growth and development of tumors. One of the main
cellular components of ECM are fibroblasts that synthesise
extracellular matrix components including proteoglycans (PG) –
complex glycosylated molecules consisting of core protein and
one or more carbohydrate chains of glycosaminoglycans. PGs
are expressed on the cell surface and in extracellular matrix for
all mammalian cells and tissues, playing an important role in
cell–cell and cell–matrix interactions and signaling.
We have hypothesised that proteoglycans are related to trans-
formation of normal ECM to cancer-associated matrix under the
influence of prostate cancer cells, and understanding of the
mechanism this transformation is very important issue. Thus,
the aim of our work was to investigate a possible involvement
of proteoglycans in the transformation normal fibroblasts to
cancer-associated fibroblasts (CAFs). To study this problem, we
co-cultivated fibroblasts with normal prostate cells (PNT2) and
prostate cancer cells with different physiological characteristics
(LNCaP, PC3, DU145) with subsequent separation of the cells and
proteoglycans expression analysis.
Firstly, we co-cultivated human fibroblasts with normal pros-
tate epithelial cell PNT2. Expression patterns of main proteogly-
cans (syndecan-1, glypican-1, perlecan, aggrecan, versican,
decorin, lumican, CSPG4/NG2, brevican) were determined in
fibroblasts before and after co-culture with PNT2 cells using RT-
PCR analysis. It was shown that after co-culture the total level
of proteoglycans expression in fibroblasts was reduced by
2-fold, although the fibroblasts expressed a similar set of proteo-
glycans with the exception of CSPG4/NG2 (which was completely
disappeared). The results suggest that normal prostate cells PNT2
affect composition and transcriptional activity of proteoglycans
in PNT2-exposed fibroblasts compared with fibroblast monocul-
ture, and this is a normal process of mutual adaptation of these
cells to each other.
At the next step, fibroblasts were co- cultivated with prostate
cancer cells of various rate of aggressiveness (hormone-
dependent non-metastatic LNCaP cells, hormone-independent
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